IP-10 has been observed to inhibit the growth of malignancies such as cervical cancer through anti-angiogenic and anti-viral mechanisms [25], while it has been observed to promote growth of malignancies such as breast cancer through the CXCR3-A receptor variant [24]. This evidence concerns the gene CXCL10 and cervical carcinoma.